EFFECT OF MALEIMIDE DERIVATIVE PROTEIN KINASES INHIBITOR WITH ANTITUMOR ACTIVITY ON MEGAKARYOCYTOPOIESIS OF RATS

L. Byelinska

Abstract


The effect of the inhibitor protein kinases maleimidederivative MI-1 (1-(4-Cl-benzyl)-3-Cl-4-(CF3-phenylamino)-1Н-pyrrole-2,5-dione) with antitumor activity at doses at five times (13.5 mg/kg) and ten times (27 mg/kg) the effective dose for subacute exposure onmorphofunctional state of bone marrow megakaryocytes and platelet count in the blood of rats have been studied. MI-1 at the dose of 2.7 mg/kg (effective antitumor – decreases the number of colon tumors and the affected area of the colon of rats) during 14 days does not changethe count of plateletsin the blood and megakaryocytes, which form platelets, in the bone marrow comparedto the untreated control group. Increasing the dose of MI-1 to 5- and 10-times (13.5 and 27 mg / kg, respectively) leads to a decrease in the number of platelets in the blood (p=0.012; p=0.027, respectively) without changes in the number of megakaryocytes in the bone marrow compared to the untreated control. Analysis of the morphofunctional state of megakaryocytes at the10-fold increased dose of MI-1 indicatesan increase in immature promegakaryocytes, hyposegmented and micromegakaryocytes to reduce background mature polichromatophilicand oxyphilicmegakaryocytes and hypersegmented and giant cells. Megakaryocytopoiesis revealed changes under the influence of MI-1 in 10-times the effective dose testify delay differentiation of megakaryocytes, which causes a decrease platelet production and, including their concentration in the altered areas of microcirculation in various tissues, leading to thrombocytopenia in the blood of rats.

Keywords


maleimide derivative; protein kinases inhibitor; megakaryocytes; platelets

References


High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients–final analysis of a randomized, multicenter, phase III trial. / A. L. Petzer, D. Fong, T. Lion et al. // Haematologica, 2012. – Vol. 97, N 10. – P.1562–1569.

Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy / I. O. Sviezhentseva, T. P. Perekhrestenko, D. I. Bilko et al. // Experimental Oncology, 2015. – Vol. 37, N 1. – P. 70–72.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial / J. E. Cortes, D.-W. Kim, H. M. Kantarjian et al. // J. of Clinical Oncology, 2012. – Vol. 30, N 28. – P. 3486–3492.

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up / R. Larson, A. Hochhaus, T. P. Hughes et al. // Leukemia, 2012. – Vol. 26, N 10. – P. 2197–203.

Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target / F. Morabito, M. Gentile, J. F. Seymour et al. // Leukemia Lymphoma, 2015. – Vol. 56, N 12. P. 3250–3256.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera / A. M. Vannucchi, J. J. Kiladjian, M. Griesshammer et al. // N. Engl J. Med., 2015. – Vol. 372, N 5. – P. 426–435.

Mechanisms of resistance in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors / T. Perekhrestenko, M. Diachenko, I. Sviezhentseva et al. // Georgian Med News, 2015. – Vol. 240. – P. 43–50.

Bixby D. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance / D. Bixby, M. Talpaz // Hematology. American Society of Hematology. Education Program, 2009. – P. 461–476.

In Silico Design of Protein Kinase Inhibitors: Successes and Failures / G. G. Dubinina, O. O. Chupryna, M. O. Platonov et al. // Anticancer Agents Med Chem., 2007. – Vol. 7(2). – P. 171–88.

Dubinina G. G. Compound of 1,4-disubstituted 5-amino-1,2dihydropyrrole-3-one having anticancer activity / G. G. Dubinina, Yu. M. Volovenko. – Pat. 22204 (UA). 21.02.2006. Appl. U200601855. 25.04.2007.

Antiproliferative activity of the new derivatives of 1-(4-R-benzyl)-3R1-4-(R2-phenylamino)-1Н-pyrrole-2,5-dione / G.G. Dubinina, S. M. Golovach, V. O. Kozlovsky et al. // J. Organ ta Farm Khimii (Ukraine), 2007. – Vol. 5, N 1. – P. 39–49.

Garmanchuk L. V. MI-1 – derivative of maleimide inhibits cell cycle progression in tuomor cells of epithelial origin / L. V. Garmanchuk, E.O. Denis, V.V. Nikulina et al. // Biopolymers and Cell, 2013. – Vol. 29, N 1. – P. 70–74.

Lynchak O.V. The influence of the maleimide derivative on the condidtion of the normal rat liver and bowel and with chemical-induced carcinogenesis of the colon. Synopsis Dissertat. For Scientif. Degree of Candidate the Biol Scienc. Кyiv, 2010:1–20.

Potential cytostatic effect of the Maleimide derivative 1-(4-Сlbenzyl)-3-Cl-4-(CF3-phenylamino)-1Н-pyrrole-2,5-dione / L.V. Garmanchuk, O.V. Linchak, V.V. Niculina et al. // Eksperimental'naya i Klinicheskaya Farmakologiya. –2013. – Vol. 76, N 8. – P. 39–42.

Byelinska I. V. Hematological effects of the protein kinases inhibitor maleimide derivative of dimethylhydrazine-induced colorectal carcinogenesis of rats / I.V. Byelinska, O. V. Lynchak, T. V. Rybalchenko et al. // Fiziolohichnyǐ zhurnal (Ukrain), 2014. – Vol. 60, N 4. – P. 40–49.

Effect of maleimide derivative on oxidative stress and glutathione antioxidant system in 1,2–dimethylhydrazine induced colon carcinogenesis in rat / O. Filinska, S. Yablonska, S. Mandryk et al. // Annales Universitatis Mariae Curie-Sklodowska. Sectio DDD: Pharmacia, 2010. – Vol. 23, N 2. – P. 189–192.

State of the liver antioxidant system and content of matrix metalloproteinase-2 of large intestine under the effect of maleimide derivative in experimental colon carcinogenesis in rats / O. M. Filinska, S. V. Yablonska, S. Y. Mandryk et al. // Ukrain'skyi biokhimicheskiy zhurnal, 2010. – Vol. 82, N 4. – P. 69–77.

Morphofunctional state of blood cells after chronic exposure of the protein kinase inhibitor maleimide derivative / I.V. Byelinska, O.V. Lynchak, S.M. Tsyvinska et al. // Fiziolohichnyǐ zhurnal (Ukraine), 2015. – Vol. 61, N 4. – P. 71–77.

Effect of maleimide derivative on the morpho-functional state of the kidney in experimental colon carcinogenesis in rats / I. V. Kharchuk, O.M. Filins'ka, S.V. Yablons'ka et al. // Fiziolohichnyǐ zhurnal (Ukraine), 2010. – Vol. 56, N 6. – P. 62–69.

The structure functional status of rat kidney and pancreas after the long-term influence of novel targeted-action compound – maleimide derivative / I. V. Kharchuk, O. M. Filinska, S. V. Yablonska et al. // Reports of the National Academy of Sciences of Ukraine, 2010. – N 7. – P. 150–154.

Regulation of Hematopoietic Stem Cells by the Steel Factor/KIT Signaling Pathway / D. Kent, M. Copley, C. Benz et al. // Clinical Cancer Research, 2008. – Vol. 14, N 7. – P. 1926–1930.

JAKs, STATs and Src kinases in hematopoiesis / S.G. Rane, E.P. Reddy et al. // Oncogene, 2002. – N 21. – P. 3334–3358.

Theroleof PKC and PDK1 in monocyte lineage specification by Ras / L. Pearn, J. Fisher, A.K. Burnett, R.L. Darley // Blood., 2007. – Vol. 109, N 10. – P. 4461–4469.

Comparative Analysis of the Antineoplastic Activity of C60 Fullerene with 5-Fluorouracil and Pyrrole Derivative In Vivo / O.V. Lynchak, Yu.I. Prylutskyy, V.K. Rybalchenko et al. // Nanoscale Research Lett., 2017. – Vol. 12, N 1. – P. 1-8.

Alekseev V.V. Medical laboratory technology. Manual of Clinical Laboratory Diagnostics / V.V. Alekseev, A.I. Karpishchenko – Moscow : GEOTAR-Media, 2012.

Byelinska I.V. Megakaryocytes morphology in indiopathic (primary) myelofibrosis / I.V. Byelinska, I.N. Kabachenko, I.S. Dyagil // Reports of Practical Oncology and Radiotherapy, 2004. – Vol. 9, N 6. – P. 223–228.

Grzhibovskiy A. M. Analysis of three or more independent groups of quantitative data / A.M. Grzhibovskiy // Ecology of human (rus.), 2008. – N 3. – P. 50–58.

Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release / G. Mattia, F. Vulcano, L. Milazzo et al. // Blood., 2002. – Vol. 99. – P. 888–897.

Deutsch V.R. Megakaryocyte development and platelet production / V.R. Deutsch, A. Tomer // British Journal of Haematology, 2006. – Vol. 134, N 5. – P. 453–466.

Understanding platelet generation from megakaryocytes: implications for in vitro–derived platelets / X. Sim, M. Poncz, P. Gadue et al. // Blood., 2016. – Vol.127, N 10. – P. 1227–1233.

Abnormal megakaryocyte development and platelet function in Nbeal22/2 mice / H.A. Kahr Walter, R.W. Lo, L. Li et al. // Blood., 2013. – Vol. 122, N 19. – P. 3349–3358.

Developmental changes in human megakaryopoiesis / O. Bluteau, T. Langlois, P. Rivera-Munoz et al. // Journal of Thrombosis and Haemostasis, 2013. – Vol. 11, N 9. – P. 1730–1741.

Pitchford S.C. VEGFR1 timulates a CXCR4–dependent translocation of megakaryocytes to the vascular niche, enhancing platelets production in mice / S.C. Pitchford, T. Lodie, S.M. Rankin // Blood., 2012. – Vol. 120, N 14. – P. 2787–2795.

VEGFR–3 is expressed on megakaryocyte precursors in the murine bone marrow and plays a regulatory role in megakaryopoiesis / W. Thiele, J. Krishnan, M. Rothley et al. // Blood., 2012. – Vol. 120, N 9. – P. 1899–1907.

Thrombopoietin (TPO) induces c-myc expression through a PI3K- and MAPK-dependent pathway that is not mediated by Akt, PKCζ or mTOR in TPO-dependent cell lines and primary megakaryocytes / S Chanprasert, A.E. Geddis, C. Barroga et al. // Cellular Signalling, 2006. – Vol. 18, N 8. – P. 1212–1218.

PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27Kip1 / T. Nakao, A.E. Geddis, N.E. Fox et al. // Cell Cycle, 2008. – Vol. 7, N 2. – P. 257–266.

PDK1 regulates platelet activation and arterial thrombosis / X. Chen, Y. Zhang, Y. Wang et al. // Blood., 2013. – Vol. 121, N 18. – P. 3718–3726.

Yena M.S. Comparative Influence of Cytostatics Maleimide Derivative and 5-Fluoruracil on Rat Caecum Mucosa / M.S. Yena, H.M. Kuznietsova, V.K. Rybalchenko // Bulletin of Problems Biology and Medicine, 2014. – Vol. 4, N 3. – P. 133–137.

Effect of different doses of protein kinase inhibitor maleimide derivative on state of rat caecum mucosa] / M.S. Yena, H.M. Kuznietsova, O.V. Lynchak et al. // Problems of Ecologycal and Medical Genetics and Klinical Immunology, 2013. – Vol. 6, N 120. – P. 21–27.

Effect of dihydropyrrol and maleimide derivatives on the state of the liver and colon in normal rats and those with colorectal carcinogenesis induced by dimethylhydrazine / H.M. Kuznietsova, O.V. Lynchak, M.O. Danylov et al. // Ukrainskiǐ biokhimicheskiǐ zhurnal, 2013. – Vol. 85, N3. – P. 62-67.


Refbacks

  • There are currently no refbacks.